Go to content

A long-term population-based study of lymphoplasmacytic lymphoma and Waldenström macroglobulinemia in Ontario, Canada

Share

Lymphoplasmacytic lymphoma (LPL) including Waldenström macroglobulinemia (WM) is a rare type of B-cell malignancy with an evolving treatment landscape. Real-world data on long-term outcomes, particularly with newer agents, are limited. We sought to characterize treatment outcomes in a contemporary, population-based cohort of patients with LPL or WM. We conducted a retrospective study using linked administrative databases in Ontario, Canada, identifying all adult patients with the International Classification of Diseases code diagnosis of WM or LPL from 2005 to 2023. Primary outcome was overall survival (OS); secondary outcomes included time to second-line therapy and immunoglobulin M (IgM) response. We identified 1986 patients (mean age, 71.8 years), of whom 51% were documented as having LPL and 49% were documented as having WM. Over a median follow-up of 4.2 years, 1117 (56.2%) patients received systemic therapy. The median OS among the overall cohort (N = 1986) was 10.1 years (95% confidence interval, 9.5-11.3). Treatment patterns evolved significantly: CVP (cyclophosphamide, vincristine, and prednisone) with or without anti-CD20 was common from 2005 to 2009, but from 2015 to 2023, bendamustine with or without anti-CD20 became the dominant regimen, followed by Bruton tyrosine kinase inhibitors (BTKi). Compared with BTKi, CVP, and other regimens, bendamustine with or without anti-CD20 was associated with the most favorable OS (median, 11.4 years; P < .0001) and the highest rates of IgM response >90% (26.4%; P < .0001). In this large population-based study, OS in patients with LPL or WM was robust. Treatment patterns have shifted to predominantly bendamustine-based regimens, which are associated with favorable survival and deep IgM responses in a real-world setting.

Information

Citation

Pandey A, Gunka B, Aljama MA, Mozessohn L, Podolsky S, Calzavara A, Berinstein NL. Blood Neoplasia. 2026 Sep 8;3(4):100301.

View Source

Contributing ICES Scientists

Research Programs

Associated Sites